DSP-3235

Generic Name: DSP-3235

Clinical Trials

Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

Phase 2

Active, not recruiting

Conditions: Postbariatric Hypoglycemia

Interventions: Drug: Mizagliflozin
Drug: Placebo

First Posted Date: 2023-02-10

Last Posted Date: 2024-11-14

Lead Sponsor: Vogenx, Inc.

Target Recruit Count: 15

Registration Number: NCT05721729

Locations: 🇺🇸
Stanford, Palo Alto, California, United States
🇺🇸
University of Colorado / Anschutz Medical Campus, Aurora, Colorado, United States

Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects

Phase 2

Completed

Conditions: Postbariatric Hypoglycemia

Interventions: Drug: Mizagliflozin

First Posted Date: 2022-09-15

Last Posted Date: 2024-06-25

Lead Sponsor: Vogenx, Inc.

Target Recruit Count: 9

Registration Number: NCT05541939

Locations: 🇺🇸
Stanford, Palo Alto, California, United States
🇺🇸
University of Colorado / Anschutz Medical Campus, Aurora, Colorado, United States

Phase II Study of KWA-0711 in Patients With Chronic Constipation (CC)

Phase 2

Completed

Conditions: Chronic Constipation

Interventions: Drug: KWA-0711

First Posted Date: 2015-01-22

Last Posted Date: 2017-05-22

Lead Sponsor: Kissei Pharmaceutical Co., Ltd.

Target Recruit Count: 37

Registration Number: NCT02343978

Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC)

Phase 2

Completed

Conditions: Chronic Constipation

Interventions: Drug: Placebo
Drug: KWA-0711

First Posted Date: 2014-11-02

Last Posted Date: 2017-05-22

Lead Sponsor: Kissei Pharmaceutical Co., Ltd.

Target Recruit Count: 388

Registration Number: NCT02281630

A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation

Phase 2

Completed

Conditions: Chronic Constipation

Interventions: Drug: KWA-0711
Drug: Placebo

First Posted Date: 2013-09-10

Last Posted Date: 2014-11-13

Lead Sponsor: Kissei Pharmaceutical Co., Ltd.

Registration Number: NCT01938196

A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation

Phase 2

Completed

Conditions: Chronic Constipation

Interventions: Drug: KWA-0711

First Posted Date: 2013-09-09

Last Posted Date: 2014-11-13

Lead Sponsor: Kissei Pharmaceutical Co., Ltd.

Registration Number: NCT01937663

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: GSK2330672
Drug: Placebo
Drug: GSK1614235

First Posted Date: 2012-05-30

Last Posted Date: 2017-07-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 56

Registration Number: NCT01607385

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

A Exploratory Study of KWA-0711 in Patients With Chronic Idiopathic Constipation (CIC)

Phase 2

Completed

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: KWA-0711
Drug: Placebo

First Posted Date: 2012-05-16

Last Posted Date: 2013-10-30

Lead Sponsor: Kissei Pharmaceutical Co., Ltd.

Target Recruit Count: 75

Registration Number: NCT01600001

Locations: 🇯🇵
Japan, Tokyo and Other Japanese City, Japan

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: GSK1614235
Drug: Sitagliptin
Other: Placebo

First Posted Date: 2009-09-14

Last Posted Date: 2017-06-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 72

Registration Number: NCT00976261

Locations: 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy